Rigel chasing pfizer in ra; nabs $1.2b-plus astrazeneca alliance (bioworld)

2010-02-17 | Source

Armed with some big pharma muscle in the form of a potential $1 billion-plus deal with AstraZeneca plc, Rigel Pharmaceuticals Inc. is hot on Pfizer Inc.'s heels in the race for an oral, disease-modifying rheumatoid arthritis drug.